Telix Pharmaceuticals Limited (OTCMKTS:TLPPF – Get Free Report)’s stock price was up 8% on Tuesday . The company traded as high as $7.56 and last traded at $7.56. Approximately 100 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 4,498 shares. The stock had previously closed at $7.00.
Telix Pharmaceuticals Trading Up 8.0%
The business’s fifty day moving average is $7.23 and its 200-day moving average is $8.72.
About Telix Pharmaceuticals
Telix Pharmaceuticals is a molecularly targeted radiopharmaceutical company specializing in the development and commercialisation of diagnostic and therapeutic products for oncology and rare diseases. The company leverages radioisotopes conjugated to disease-specific targeting agents, enabling precise imaging and treatment of cancerous lesions. Telix’s portfolio includes investigational imaging compounds, such as a gallium-68-labeled prostate cancer agent, alongside therapeutic candidates that deliver beta- or alpha-emitting isotopes directly to disease sites.
Telix’s lead diagnostic program focuses on positron emission tomography (PET) imaging for prostate cancer, designed to improve detection and staging accuracy.
Read More
- Five stocks we like better than Telix Pharmaceuticals
- The gold chart Wall Street is terrified of…
- What a Former CIA Agent Knows About the Coming Collapse
- Elon Musk already made me a “wealthy man”
- Unlocked: Elon Musk’s Next Big IPO
- 1,500 Banks Just Handed the Fed Your Bank Account
Receive News & Ratings for Telix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
